Business Development Representative - Network Solutions

Phreesia named one of TIME's World's Top HealthTech Companies 2026. * Published - September 25, 2026 Making care easier - in its clients' words. More than 4,700 healthcare organizations use Phreesia to make care easier for patients, practices and staff. Here's what that looks like every day. "The patient impact is undeniable." Cassandra englund-thompson, strategic project consultant, summit orthopedics. Appointment Accelerator(R) offers canceled appointments to eligible patients automatically - helping people get care sooner while keeping schedules full, without adding work for staff. "Registration is revenue." Matthew moore, chief technology innovation officer, effingham health system. Accurate registration supports cleaner claims. Upfront eligibility checks catch issues earlier. And clear, convenient payment options help patients resolve balances sooner. "Payments, scheduling and refills are exactly where AI helps." Sneha Patel, CEO, COO, MPAS, PA-C, metroplex medical centres. "Instead of hiring more FTEs to do manual tasks, we're using technology to solve problems at scale," Patel said. "Phreesia was a strong partner for us from the beginning." Troy moore, CEO, Ellinwood hospital & clinic. Technology creates more value when it becomes a chance to improve how the organization operates. For Ellinwood, that meant involving the right people, looking beyond any one workflow and staying open to change. Making care easier every day. Today, Phreesia supports more than 180 million patient visits each year - about 1 in 6 visits across the U.S. Across its network, 85% of patients check themselves in, saving staff more than five minutes per self-service check-in. And 97% of patients report being satisfied with their Phreesia experience. For more than 20 years, Phreesia has focused on technology patients use, teams value and practices can build on. Phreesia is honored to be named one of TIME's World's Top HealthTech Companies 2026 - and excited to keep making care easier every day, for everyone. G2 Leader Capterra Shortlist KLAS Best in KLAS HITRUST CRF SOC 2 TYPE 2 The best-performing practices run on Phreesia. See what changes when your platform closes the loop - from first call to final payment.

Insider selling: Phreesia (NYSE:PHR) General Counsel sells $67,152.96 in stock. September 22, 2026 Key points. * Phreesia General Counsel Allison Hoffman sold 6,662 shares at an average price of $10.08, generating $67,152.96. The Rule 10b5-1 sale covered tax withholding tied to vested equity awards and reduced her ownership by 2.44%. * Phreesia shares rose 0.7% to $10.11, giving the company a market capitalization of approximately $627 million. The stock remains well below its 52-week high of $25.00. * The company's latest quarterly revenue increased 10.4% year over year to $129.46 million, but earnings of $0.03 per share missed analyst expectations of $0.09. Analysts maintain a consensus Hold rating with a $14.00 price target. * Five stocks we like better than Phreesia. Phreesia, Inc. (NYSE:PHR - Get Free Report) General Counsel Allison Hoffman sold 6,662 shares of the company's stock in a transaction on Monday, September 21st. The stock was sold at an average price of $10.08, for a total transaction of $67,152.96. Following the completion of the transaction, the general counsel directly owned 266,574 shares in the company, valued at $2,687,065.92. This trade represents a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Phreesia stock up 0.7%. Shares of NYSE:PHR traded up $0.07 during midday trading on Tuesday, hitting $10.11. 476,751 shares of the stock were exchanged, compared to its average volume of 1,449,417. The company has a market capitalization of $627.22 million, a PE ratio of 59.44 and a beta of 0.86. Phreesia, Inc. has a 52-week low of $7.77 and a 52-week high of $25.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.76 and a current ratio of 1.76. The business's fifty day simple moving average is $11.15 and its two-hundred day simple moving average is $10.32. Phreesia (NYSE:PHR - Get Free Report) last issued its earnings results on Wednesday, September 2nd. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.06). Phreesia had a return on equity of 5.22% and a net margin of 2.06%.The firm had revenue of $129.46 million during the quarter, compared to analyst estimates of $129.06 million. During the same period in the previous year, the company earned $0.01 earnings per share. The business's revenue for the quarter was up 10.4% on a year-over-year basis. As a group, research analysts predict that Phreesia, Inc. will post 0.33 earnings per share for the current fiscal year. Wall Street analyst weigh in. PHR has been the topic of several recent research reports. Robert W. Baird raised their price objective on shares of Phreesia from $10.00 to $11.00 and gave the company a "neutral" rating in a research report on Friday, September 4th. Weiss Ratings cut shares of Phreesia from a "sell (d+)" rating to a "sell (d)" rating in a report on Friday, September 4th. Truist Financial increased their target price on shares of Phreesia from $11.00 to $12.00 and gave the stock a "hold" rating in a research report on Thursday, May 28th. Needham & Company LLC reaffirmed a "buy" rating and issued a $14.00 price target on shares of Phreesia in a research report on Monday, August 31st. Finally, Royal Bank Of Canada reiterated an "outperform" rating and set a $19.00 price target on shares of Phreesia in a research note on Thursday, September 3rd. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $14.00. Discover more Portfolio Management Tools Research tools access Institutional investors weigh in on Phreesia. Several hedge funds have recently modified their holdings of the business. EverSource Wealth Advisors LLC increased its position in Phreesia by 1,119.8% during the first quarter. EverSource Wealth Advisors LLC now owns 3,269 shares of the company's stock worth $27,000 after acquiring an additional 3,001 shares during the period. New York State Teachers Retirement System bought a new stake in Phreesia in the 1st quarter valued at $44,000. Rockefeller Capital Management L.P. boosted its holdings in Phreesia by 354.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company's stock valued at $47,000 after purchasing an additional 2,149 shares during the period. Allworth Financial LP acquired a new stake in Phreesia in the 2nd quarter worth $58,000. Finally, Essential Partners LLC grew its position in Phreesia by 2,016.6% in the 1st quarter. Essential Partners LLC now owns 9,313 shares of the company's stock worth $78,000 after purchasing an additional 8,873 shares during the last quarter. 92.10% of the stock is owned by institutional investors. Phreesia company profile. Phreesia, Inc is a healthcare technology company that provides software and services designed to help healthcare organizations manage patient intake and engagement. Its platform digitizes administrative and clinical processes that traditionally rely on paper forms, manual data entry, and separate payment systems. The company's offerings include digital patient check-in and registration, insurance and demographic information collection, appointment-related communications, electronic forms and consent management, patient surveys, and payment processing. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Phreesia, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phreesia wasn't on the list. While Phreesia currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely. Continue following MarketBeat

Phreesia has partnered with DeepIntent to make its ProviderConnect audiences available in the DeepIntent Audience Marketplace. ProviderConnect enables healthcare marketers to reach clinicians based on cases they are likely to see in upcoming practice, rather than using broad-reach awareness campaigns. The service draws on real-world care insights from Phreesia's product ecosystem to inform clinicians about new clinical data, safety information, and treatment options whilst maintaining privacy. Phreesia enabled more than 180 million patient visits in 2025, representing one in six visits across the US. The partnership allows brands already using DeepIntent to access Phreesia's real-time audience solution, helping healthcare marketers deliver more personalised media to providers before treatment decisions are made.